Colospan's Greece-Cyprus CG-100 deal shows a capital-light route into Europe
Eocene's subsidiary hands exclusive rights for its CE-marked bypass device to Hospital Line SA, a small deal that sits within a wider run of asset-light moves by small-cap biotechs.
What happened
On 10 November, EoCene Ltd. (EOCN) said its subsidiary Colospan has granted Hospital Line SA exclusive rights to market the CE-marked CG-100 intraluminal bypass device in Greece and Cyprus. It is Colospan's first European distribution agreement for the product.
The material available does not include financial terms, such as upfront payments, minimums, milestones or contract length. It also gives no sales expectations. The deal should therefore be read as a market-access step, not a revenue event. What is confirmed is the structure: exclusive, regional, distributor-led, and built on a product that already carries a CE mark.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Sources
- Colospan signs first European distribution deal for CG-100 bypass device in Greece and Cyprus EoCene Ltd. · 10 Nov 2026
- MacroGenics reports $288M cash and 2028 runway, putting B7-H3 ADC MGC026 in head and neck cancer first Macrogenics Inc · 13 Nov 2026
- Xenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patient Xenetic Biosciences, Inc. · 13 Nov 2026
- Longeveron seeks FDA meeting after ELPIS II miss and starts strategic alternatives review Longeveron Inc. · 12 Nov 2026
- Silence Therapeutics narrows Q3 loss as Merck KGaA deal and divesiran data take centre stage Silence Therapeutics plc · 12 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Vir's Follow-On Tests Whether Open Equity Windows Favor Platform Stories Over Small-Cap Fixes
Vir Biotechnology's unpriced offering lands the same week as a $225M Windward IPO and a string of warrant-laden small-cap raises, showing how differently capital is available across biotech.
Tenon Medical's $15.6M raise clears convertibles and Nasdaq risk, but not the funding question
The SI joint fusion maker used a quarter of financing to repay senior notes early and regain listing compliance. Peers' Q3 raises show how different the small-cap capital market has become.
IM Cannabis funds a shrinking business with converts while peers raise on scale and strategics
IM Cannabis's nine-month loss and shareholders' deficit sit against a week of financings in which strategic capital and clinical catalysts, not survival needs, set the terms.